Clinical observation of different doses of rituximab for the treatment of severe pemphigus: A single-center prospective cohort study

Published: 27 June 2022| Version 1 | DOI: 10.17632/v4hb3cp7zt.1
Contributors:
,
,
,
,
,
,
,
,

Description

Clinical observation of different doses of rituximab for the treatment of severe pemphigus: A single-center prospective cohort study Supplemental Figure 1 (A, B) Percentage of peripheral B and T lymphocytes. (C, D) Anti-desmoglein (Dsg) 1 and Dsg 3 enzyme-linked immunosorbent assay (ELISA) indices. The dashed line in panels C and D represents the cutoff values proposed by the manufacturer for the anti-Dsg 1 and Dsg 3 antibodies.

Files

Categories

Dermatology, Rituximab, Prospective Cohort Study, Pemphigus, Bullous Disease

License